Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Lipocine Inc. (LPCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0900-0.0700 (-6.03%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1600
Open1.1500
Bid1.0700 x 2200
Ask1.0900 x 1800
Day's Range1.0600 - 1.1600
52 Week Range0.9810 - 2.4200
Volume873,993
Avg. Volume674,998
Market Cap96.237M
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-0.2830
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • Benzinga

    5 Penny Stocks Insiders Are Buying

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Castlight Health The Trade: Castlight Health, Inc. (NYSE: CSLT) CEO Maeve Omeara acquired a total of 186290 shares . The i

  • Zacks Small Cap Research

    LPCN: Third Quarter Update

    By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Third Quarter 2021 Financial and Operational Results On November 10, 2021 Lipocine (NASDAQ:LPCN) filed its Form 10-Q and posted its earnings release for the three month period ending September 30, 2021. Highlights for the third quarter 2021 and to-date include: ➢ Settlement with Clarus Therapeutics - July 2021 ➢ LPCN 1144

  • PR Newswire

    Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.

Advertisement
Advertisement